Loading
Runs Japan's largest first-in-human oncology unit, where many Daiichi Sankyo DXd ADCs were first given to patients.
Noboru Yamamoto is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital in Tokyo. He runs Japan's largest first-in-human oncology unit, where many of the Daiichi Sankyo DXd antibody-drug conjugates were first given to patients, including trastuzumab deruxtecan and datopotamab deruxtecan. His publications include the TROPION-PanTumor01 first-in-human study of datopotamab deruxtecan in non-small-cell lung cancer, the REMORA phase 2 trial of lenvatinib in advanced thymic carcinoma, and a phase 1 study of the anti-CCR4 antibody mogamulizumab combined with nivolumab in solid tumours. His interests are phase 1 trials, drug development and lung cancer.
Shares National Cancer Center Hospital, Daiichi Sankyo, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares National Cancer Center Hospital, Daiichi Sankyo, Trastuzumab deruxtecan.
Shares Datopotamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).